Under pressure: The search for the essential mechanisms of hypertension

Nature Medicine

Volumn 17, Issue 11, 2011, Pages 1402-1409

  Coffman, Thomas M ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ATP2B1 PROTEIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CYTOCHROME P450 17A1; ENDOTHELIN 3; FIBROBLAST GROWTH FACTOR 5; HYDRALAZINE; MYELODYSPLASIA SYNDROME PROTEIN 1; NATRIURETIC PEPTIDE CLEARANCE RECEPTOR 3; PLEKHA7 PROTEIN; SH2B3 PROTEIN; TRANSCRIPTION FACTOR TBX3; TRANSCRIPTION FACTOR TBX5; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL CACNB2; ZINC FINGER PROTEIN 652;

ABLATION THERAPY; ADRENERGIC SYSTEM; AUTOIMMUNE DISEASE; BLOOD PRESSURE REGULATION; DRUG EFFICACY; GENETIC ASSOCIATION; HUMAN; HYPERTENSION; IMPOTENCE; KIDNEY DENERVATION; KIDNEY FUNCTION; LETHARGY; LIFESTYLE MODIFICATION; NATRIURESIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SALT INTAKE; STROKE; VASCULAR RESISTANCE; XEROSTOMIA;

ANIMALS; BLOOD PRESSURE; HUMANS; HYPERTENSION; KIDNEY; SIGNAL TRANSDUCTION; SKIN; SODIUM;

EID: 81255195551     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2541     Document Type: Review

References (44)

1. Lawes, C.M., Vander Hoorn, S. & Rodgers, A. Global burden of blood-pressure related disease. Lancet 371, 1513-1518 (2008). (Pubitemid 351626187)
2. The VA Cooperative Study Group. Effects of treatment on morbidity of hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. J. Am. Med. Assoc. 202, 1028-1034 (1967).
3. Chobanian, A. The hypertension paradox: more uncontrolled disease despite improving therapy. N. Engl. J. Med. 361, 878-887 (2009).
4. Guyton, A.C. Blood pressure control-special role of the kidneys and body fluids. Science 252, 1813-1816 (1991). (Pubitemid 21917099)
5. Meneton, P., Jeunmaitre, X., de Wardener, H. & MacGregor, G. LInks between dietary salt intake, renal salt handling, blood pressure and cardiovascular disease. Physiol. Rev. 85, 679-715 (2005). (Pubitemid 40404639)
6. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Group & the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J. Am. Med. Assoc. 288, 2981-2997 (2002).
7. Rettig, R. & Grisk, O. The kidney as a determinant of genetic hypertension: evidence from renal transplantation studies. Hypertension 46, 463-468 (2005). (Pubitemid 41376819)
8. Crowley, S.D. et al. Angiotensin II causes hypertension and cardiac hypertrophy via its receptors in the kidney. Proc. Natl. Acad. Sci. USA 103, 17985-17990 (2006). (Pubitemid 44852272)
9. Crowley, S.D. et al. Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system. J. Clin. Invest. 115, 1092-1099 (2005). (Pubitemid 40489414)
10. Gurley, S.B. et al. AT1A Angiotensin receptors in the renal proximal tubule regulate blood pressure. Cell Metab. 13, 469-475 (2011).
11. Li, H. et al. Renal proximal tubule angiotensin AT1A receptors regulate blood pressure. Am. J. Physiol. Regul. Integr. Comp. Physiol. 298, R1209-R1211 (2011).
12. Navar, L.G., Kobori, H., Prieto, M.C. & Gonzalez-Villalobos, R.A. Intratubular renin-angiotensin system in hypertension. Hypertension 57, 355-362 (2011).
13. Machnik, A. et al. Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nat. Med. 15, 545-552 (2009).
14. Guzik, T.J. et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J. Exp. Med. 204, 2449-2460 (2007). (Pubitemid 47529329)
15. Cowley, A.W. Long-term control of arterial blood pressure. Physiol. Rev. 72, 231-300 (1992).
16. Wirth, A. et al. G12-G13-LARG-mediated signaling in vascular smooth muscle is required for salt-induced hypertension. Nat. Med. 14, 64-68 (2008).
17. Guilluy, C. et al. The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure. Nat. Med. 16, 183-190 (2010).
18. Packard, R.R., Lichtman, A.H. & Libby, P. Innate and adaptive immunity in atherosclerosis. Semin. Immunopathol. 31, 5-22 (2009).
19. Muller, D.N. et al. Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am. J. Pathol. 161, 1679-1693 (2002). (Pubitemid 35265527)
20. Nataraj, C. et al. Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J. Clin. Invest. 104, 1693-1701 (1999). (Pubitemid 30053186)
21. Madhur, M.S. et al. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension 55, 500-507 (2010).
22. Crowley, S. et al. Lymphocyte responses exacerbate angiotensin II-dependent hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 298, R1089-R1097 (2009).
23. Vinh, A. et al. Inhibition and genetic ablation of the B7/CD28 T-cell costimulation axis prevents experimental hypertension. Circulation 122, 2529-2537 (2010).
24. Marvar, P.J. et al. Central and peripheral mechanisms of T-lymphocyte activation and vascular inflammation produced by angiotensin II induced hypertension. Circ. Res. 107, 263-270 (2010).
25. Lifton, R.P., Gharavi, A. & Geller, D. Molecular mechanisms of human hypertension. Cell 104, 545-556 (2001). (Pubitemid 32201949)
26. Levy, D. et al. Genome-wide association study of blood pressure and hypertension. Nat. Genet. 41, 677-687 (2009).
27. Newton-Cheh, C. et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat. Genet. 41, 666-676 (2009).
28. Kato, N. et al. Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. Nat. Genet. 43, 531-538 (2011).
29. The International Consortium for Blood Pressure Genome-Wide Association Studies et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 478, 103-109 (2011).
30. Auchus, R.J. The genetics, pathophyioslogy and management of human deficiencies of P450c17. Endocrinol. Metab. Clin. North Am. 30, 101-119 (2001). (Pubitemid 32381716)
31. John, S.W. et al. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science 267, 679-681 (1995).
32. Newton-Cheh, C. et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat. Genet. 41, 348-353 (2009).
33. Ge, Y. et al. Collecting duct specific knockout of the ednothelin B recpetor causes hypertension and sodium retention. Am. J. Physiol. Renal. Physiol. 291, F1274-F1280 (2006). (Pubitemid 44889187)
34. Gudbjartsson, D.F. et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat. Genet. 41, 342-347 (2009).
35. Cirulli, E.T. & Goldstein, D.B. Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat. Rev. Genet. 11, 415-425 (2010).
36. Ji, W. et al. Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat. Genet. 40, 592-599 (2008). (Pubitemid 351601207)
37. Choi, M. et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 331, 768-772 (2011).
38. Sacks, F.M. et al. Effects on blood pressure of reduced dietary sodium and the dietary approches to stop hypertension (DASH) diet. N. Engl. J. Med. 344, 3-10 (2001). (Pubitemid 32064838)
39. Tissot, A.C. et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 371, 821-827 (2008). (Pubitemid 351323893)
40. Malpas, S.C. Sympathetic nervous system overactivity and its role in the development of cardiovascular disease. Physiol. Rev. 90, 513-557 (2010).
41. Mu, S. et al. Epigenetic modulation of the renal β-adrenergic-WNK4 pathway in salt-sensitive hypertension. Nat. Med. 17, 573-580 (2011).
42. Simplicity HTN-2 Investigators et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Simplicity HTN-2 Trial): a randomised controlled trial. Lancet 376, 1903-1909 (2010).
43. Krum, H. et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373, 1275-1281 (2009).
44. Heusser, K. et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 55, 619-626 (2010).